Development of single-cycle replicable human immunodeficiency virus 1 mutants

Acta Virologica

Volumn 55, Issue 1, 2011, Pages 15-22

  Zabihollahi, R ^a,b   Sadat, S M ^a,c   Vahabpour, R ^a   Aghasadeghi, M R ^a   Memarnejadian, A ^a   Ghazanfari, T ^d   Salehi, M ^b   Rezaei, A ^b   Azadmanesh, K ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

^d SHAHED UNIVERSITY   (Iran)

Author keywords

AIDS vaccine; Human immunodeficiency virus 1; Mutants; Single cycle replicable virions

Indexed keywords

THROMBOSPONDIN; G PROTEIN, VESICULAR STOMATITIS VIRUS; INTEGRASE; MEMBRANE PROTEIN; POL PROTEIN; RNA DIRECTED DNA POLYMERASE; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANTIGENICITY; ARTICLE; CELL STRAIN HEK293; CELL TYPE; CONTROLLED STUDY; ELECTRON MICROSCOPY; EMBRYO; GENETIC SUSCEPTIBILITY; GENETIC TRANSFECTION; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOUSE; NONHUMAN; PLASMID; SNGLE CYCLE REPLICABLE; SPLEEN CELL; VIRUS MUTANT; VIRUS REPLICATION; ANIMAL; BIOSYNTHESIS; BLOOD; CELL LINE; FRAMESHIFT MUTATION; GENE DELETION; GENETICS; METABOLISM; PHYSIOLOGY; STRUCTURAL GENE; VIRION;

HUMAN IMMUNODEFICIENCY VIRUS 1; VESICULAR STOMATITIS VIRUS;

ANIMALS; CELL LINE, TRANSFORMED; FRAMESHIFT MUTATION; GENE DELETION; GENES, POL; HEK293 CELLS; HIV INTEGRASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRAL ENVELOPE PROTEINS; VIRION; VIRUS REPLICATION;

EID: 79957533897     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: 10.4149/av_2011_01_15     Document Type: Article

References (29)

1. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA (1986): Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59, 284-291.
2. Alexander L, Illyinskii PO, Lang SM, Means RE, Lifson J, Mansfield K, Desrosiers RC (2003): Determinants of increased replicative capacity of serially passaged simian immunodeficiency virus with nef deleted in rhesus monkeys. J. Virol. 77, 6823-6835.
3. Anglaret X (2008): Global AIDS epidemic: from epidemiology to universal treatment. Rev. Med. Interne 29 (Suppl. 3), S269-S273.
4. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, Ruprecht RM (1995): Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267, 1820-1825.
5. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, Penninck D, Bronson R, Greene MF, McClure HM, Martin LN, Ruprecht RM (1999): Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat. Med. 5, 194-203.
6. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L (1983): Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868-871.
7. Bayer M, Kantor B, Cockrell A, Ma H, Zeithaml B, Li X, McCown T, Kafri T (2008): A large U3 deletion causes increased in vivo expression from a nonintegrating lentiviral vector. Mol. Ther. 16, 1968-1976.
8. Biel SS, Gelderblom HR (1999): Diagnostic electron microscopy is still a timely and rewarding method. J. Clin. Virol. 13, 105-119.
9. Buffa, V, Negri, D R, Leone P, Borghi M, Bona R, Michelini Z, Compagnoni D, Sgadari C, Ensoli B, Cara A (2006): Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo. Viral Immunol. 19, 690-701.
10. Cavrois M, Neidleman J, Yonemoto W, Fenard D, Greene WC (2004): HIV-1 virion fusion assay: uncoating not required and no effect of Nef on fusion. Virology 328, 36-44.
11. Cheemeh PE, Montoya ID, Essien EJ, Ogungbade GO (2006): HIV/AIDS in the Middle East: a guide to a proactive response. J. R. Soc. Promot. Health 126, 165-171.
12. Cristofaro JV, Rausch JW, Le Grice SF, DeStefano JJ (2002): Mutations in the ribonuclease H active site of HIV-RT reveal a role for this site in stabilizing enzyme-primer-template binding. Biochemistry 41, 10968-10975.
13. Dudek T, Knipe DM (2006): Replication-defective viruses as vaccines and vaccine vectors. Virology 344, 230-239.
14. Freed EO (2001): HIV-1 replication. Somat. Cell. Mol. Genet. 26, 13-33.
15. Logan AC, Haas DL, Kafri T, Kohn DB (2004): Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration. J. Virol. 78, 8421-8436.
16. Madani N, Hubicki A M, Perdigoto AL, Springer M, Sodroski J (2007): Inhibition of human immunodeficiency virus envelope glycoprotein-mediated single cell lysis by low-molecular-weight antagonists of viral entry. J. Virol. 81, 532-538.
17. McBurney SP, Young KR, Nwaigwe CI, Soloff AC, Cole KS, Ross TM (2006): Lentivirus-like particles without reverse transcriptase elicit efficient immune responses. Curr, HIV Res. 4, 475-484.
18. Memarnejadian A, Roohvand F (2010): Fusion of HBsAg and prime/boosting augment Th1 and CTL responses to HCV polytope DNA vaccine. Cell. Immunol. 261, 93-98.
19. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM (1998): Development of a self-inactivating lentivirus vector. J. Virol. 72, 8150-8157.
20. Morgan JR, LeDoux JM, Snow RG, Tompkins RG, Yarmush ML (1995): Retrovirus infection: effect of time and target cell number. J. Virol. 69, 6994-7000.
21. Mukherjee S, Lee HL, Pacchia AL, Ron Y, Dougherty JP (2007): A HIV-2-based self-inactivating vector for enhanced gene transduction. J. Biotechnol. 127, 745-757.
22. Nakamura T, Masuda T, Goto T, Sano K, Nakai M, Harada S (1997): Lack of infectivity of HIV-1 integrase zinc finger-like domain mutant with morphologically normal maturation. Biochem. Biophys. Res. Commun. 239, 715-722.
23. Negri DR, Michelini Z, Baroncelli S, Spada M, Vendetti S, Buffa V, Bona R, Leone P, Klotman ME, Cara A (2007): Successful immunization with a single injection of non-integrating lentiviral vector. Mol. Ther. 15, 1716-1723.
24. Rezaei A, Zabihollahi R, Salehi M, Moghim S, Tamizifar H, Yazdanpanahi N (2007): Designing a non-virulent HIV-1 strain: potential implications for vaccine and experimental research. J. Res. Med. Sci. 12, 227-234.
25. Rinke CS, Boyer PL, Sullivan MD, Hughes SH, Linial ML (2002): Mutation of the catalytic domain of the foamy virus reverse transcriptase leads to loss of processivity and infectivity. J. Virol. 76, 7560-7570.
26. Svarovskaia ES, Barr R, Zhang X, Pais GC, Marchand C, Pommier Y, Burke TR, Jr, Pathak VK (2004): Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions. J. Virol. 78, 3210-3222.
27. Wang RR, Gu Q, Wang YH, Zhang XM, Yang LM, Zhou J, Chen JJ, Zheng YT (2008): Anti-HIV-1 activities of compounds isolated from the medicinal plant Rhus chinensis. J. Ethnopharmacol. 117, 249-256.
28. Yu D, Wang W, Yoder A, Spear M, Wu Y (2009): The HIV envelope but not VSV glycoprotein is capable of mediating HIV latent infection of resting CD4 T cells. PLoS Pathog. 5, e1000633.
29. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D (1998): Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72, 9873-9880.